Glenmark Pharmaceuticals rises on initiating Phase 2b clinical trial of GBR 830

17 Apr 2018 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 579.75, up by 4.95 points or 0.86% from its previous closing of Rs. 574.80 on the BSE.

The scrip opened at Rs. 577.00 and has touched a high and low of Rs. 582.15 and Rs. 577.00 respectively. So far 4,188 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 930.00 on 11-May-2017 and a 52 week low of Rs. 517.40 on 19-Feb-2018.

Last one week high and low of the scrip stood at Rs. 585.80 and Rs. 553.50 respectively. The current market cap of the company is Rs. 16,358.00 crore.

The promoters holding in the company stood at 46.54%, while Institutions and Non-Institutions held 37.07% and 16.40% respectively.

Glenmark Pharmaceuticals has initiated Phase 2b clinical trial of GBR 830, a novel, investigational treatment for moderate-to-severe atopic dermatitis. The trial’s primary endpoint will assess the efficacy of GBR 830, compared to placebo. Secondary and exploratory trial endpoints include additional measures of efficacy, safety and pharmacodynamics. The trial enrollment is expected to begin in June 2018.

The Phase 2b, double-blind, placebo-controlled multicenter trial will randomize approximately 392 patients across four dosing arms of GBR 830 and placebo. The trial’s primary endpoint will assess the effectiveness of GBR 830, compared to placebo, on reducing the severity of atopic dermatitis as measured by Investigator’s Global Assessment (IGA).

Further, in addition to moderate-to-severe atopic dermatitis, Glenmark is evaluating the potential for conducting studies with GBR 830 for the treatment of other inflammatory autoimmune conditions where dysregulation of OX40 overexpression is implicated in disease activity.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).


Glenmark Pharma Share Price

1938.35 19.30 (1.01%)
09-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1776.20
Dr. Reddys Lab 1246.25
Cipla 1490.70
Zydus Lifesciences 919.90
Lupin 2052.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×